AM-Pharma Raises €116m To Finance Solo Phase III Trial

 
• By Mike Ward

Following Pfizer’s decision not to take up an option to acquire the Dutch company, AM-Pharma has returned to the venture capital market to get backing for a single pivotal Phase III trial of reCAP in acute kidney injury.

Euro currency
AM-Pharma Concludes Largest Fundraising To Date

More from Financing

More from Business